2018
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
Yoon J, Zisook S, Park A, Johnson GR, Scrymgeour A, Mohamed S. Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2018, 80 PMID: 30695291, DOI: 10.4088/jcp.18m12294.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, Second-GenerationAripiprazoleBupropionCost-Benefit AnalysisDepressionDepressive Disorder, MajorDrug SubstitutionDrug SynergismDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRemission InductionUnited StatesUnited States Department of Veterans AffairsVeteransConceptsIncremental cost-effectiveness ratioStandard antidepressant therapyBupropion augmentationAripiprazole augmentationAntidepressant therapyClinical trialsVeterans Affairs Medical CenterDepression Outcomes trialMental health care costsRate of remissionRandomized clinical trialsHealth care sector perspectiveICD-9 codesTreatment of depressionCost-effectiveness ratioHealth care costsCost-effective relativeCost-effectiveness analysisOutcome trialsMean ageQuick InventoryDepression diagnosisTreatment strategiesRemissionMedical Center
2012
Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression?
Dawes SE, Palmer BW, Meeks T, Golshan S, Kasckow J, Mohamed S, Zisook S. Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression? Neuropsychobiology 2012, 65: 168-172. PMID: 22456094, PMCID: PMC3701889, DOI: 10.1159/000331141.Peer-Reviewed Original ResearchConceptsSchizoaffective disorderCognitive deficitsDepression Rating Scale scoresHamilton Depression Rating ScaleFlexible-dose treatmentAntidepressant treatment responseDepression Rating ScaleTreatment of depressionMajor depressive disorderRating Scale scoresBaseline cognitive statusPlacebo groupAntidepressant medicationCurrent medicationsPlacebo augmentationFunctional disabilityCognitive composite scoreSubsyndromal depressionDepressive disorderSubsyndromal symptomsTreatment responseTreatment groupsDose treatmentScale scoreCognitive status
2010
Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates
Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates. American Journal Of Geriatric Psychiatry 2010, 18: 917-927. PMID: 20808108, PMCID: PMC3972419, DOI: 10.1097/jgp.0b013e3181d5745d.Peer-Reviewed Original ResearchConceptsAlzheimer's diseasePatients' qualityCaregiver burdenCognitive statusCaregiver Distress ScaleUsual care settingsIntensity of careLower functional capabilitySix-month changesClinical Antipsychotic TrialsProbable Alzheimer's diseasePatients' cognitive statusDiagnosis of dementiaQuality of lifeBeck Depression InventoryCATIE-ADRelationship of burdenBurden InterviewAmbulatory outpatientsPatients CorrelatePharmacologic interventionsAntipsychotic TrialsTreatment outcomesDecreased burdenCare settingsImpact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal Of Clinical Psychiatry 2010, 72: 75-80. PMID: 20868641, PMCID: PMC5052810, DOI: 10.4088/jcp.09m05258gre.Peer-Reviewed Original ResearchConceptsMajor depressive episodeSecond-generation antipsychoticsDSM-IV-defined schizophreniaCurrent major depressive episodeClinical practice recommendationsTrial of treatmentClinical practice guidelinesTreatment of depressionCalgary Depression ScaleClinical Antipsychotic TrialsSecond-generation drugsSymptoms of depressionPhase 1 analysisTardive dyskinesiaDepressive episodeChronic schizophreniaAntipsychotic TrialsPractice guidelinesDepression ScaleDepressive symptomsTreatment groupsBaseline scoresPatientsAntipsychoticsPractice recommendationsAugmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial.
Zisook S, Kasckow JW, Lanouette NM, Golshan S, Fellows I, Vahia I, Mohamed S, Rao S. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. The Journal Of Clinical Psychiatry 2010, 71: 915-22. PMID: 20361918, DOI: 10.4088/jcp.09m05699gre.Peer-Reviewed Original ResearchConceptsBaseline suicidal ideationHamilton Depression Rating ScaleDepression Rating ScaleSubthreshold depressive symptomsCalgary Depression Rating ScaleDepressive symptomsSuicidal ideationSchizoaffective disorderClinical Global Impressions-SeverityBeck Hopelessness ScaleDSM-IV-diagnosed schizophreniaRating ScaleTreatment-emergent suicidal ideationPlacebo-controlled trialSuicidal ideation measuresItem 3Citalopram augmentationFinal visitPlacebo augmentationSecondary outcomesPrimary outcomeOlder outpatientsInterSePT ScaleCitalopramPlacebo
2007
Subsyndromal Depressive Symptoms in Middle-Aged and Older Persons with Schizophrenia
Zisook S, Montross L, Kasckow J, Mohamed S, Palmer BW, Patterson TL, Golshan S, Fellows I, Lehman D, Solorzano E. Subsyndromal Depressive Symptoms in Middle-Aged and Older Persons with Schizophrenia. American Journal Of Geriatric Psychiatry 2007, 15: 1005-1014. PMID: 18056819, DOI: 10.1097/jgp.0b013e3180a725ec.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsChronic DiseaseCitalopramComorbidityDepressionDepressive Disorder, MajorDouble-Blind MethodFemaleFollow-Up StudiesHealth StatusHumansMaleMiddle AgedPlacebosPsychiatric Status Rating ScalesPsychotic DisordersSchizophreniaSchizophrenic PsychologySelective Serotonin Reuptake InhibitorsSuicideTreatment OutcomeConceptsSubsyndromal depressive symptomsDepressive symptomsOlder patientsClinical featuresSchizoaffective disorderNegative symptomsHamilton Depression Rating ScaleImportant clinical dimensionGeneral medical conditionsDepression Rating ScaleSpecific depressive symptomsMental functioningSubstantial morbiditySevere akathisiaMovement abnormalitiesChronic schizophreniaMedical conditionsDepression groupOverall psychopathologyIntervention studiesDepressive symptomatologyPatientsSymptomsOlder personsGeneral psychopathology
2001
Citalopram augmentation of antipsychotic treatment in older schizophrenia patients
Kasckow J, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste D. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. International Journal Of Geriatric Psychiatry 2001, 16: 1163-1167. PMID: 11748776, DOI: 10.1002/gps.508.Peer-Reviewed Original ResearchConceptsCitalopram augmentationScale scoreClinical Global Impression Scale scoresHamilton Depression Rating Scale scoresLarge double-blind studyDepression Rating Scale scoresAugmentation of antipsychoticsUsefulness of antidepressantsDouble-blind studySingle-blind trialMajor side effectsOlder schizophrenia patientsRating Scale scoresStable dosesElderly patientsOlder patientsAntipsychotic treatmentCitalopram groupDepressive symptomsSide effectsPatientsSchizophrenia patientsControl groupNegative symptomsAntipsychotics